Zimbabwe has declined a substantial American health deal valued at $367m (272 million pounds) spanning five years over Washington's request for confidential biological samples.
This move was revealed following a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesman later clarified that the United States was requesting health data for research and profit while was not willing to share the resulting advantages from any future vaccines.
"We must now begin the difficult and regrettable task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further talks to reach a deal acceptable to all parties so the country's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court blocked a similar health funding agreement after legal challenges were raised about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had administered assistance for the US government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral deals to boost transparency and accountability.
According to reports, Sixteen nations in Africa have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to share its genetic material and health information indefinitely, with no corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," he stated.
"In essence, our country would supply the raw materials for medical research with no certainty that the final treatments would be accessible to our people should a new health crisis arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its push of bilateral health agreements were upending frameworks already set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This system is designed to guarantee that when a nation provides its data, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how subsequent collaboration could be structured in a manner that honours the sovereignty and interests of each country."
Health Experts Response
A leading public health body stated it recognised the official position, but urged that negotiations need to persist since much of the nation's HIV programmes depended on foreign aid.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group added.
The situation highlights the complex tensions between accepting much-needed foreign assistance and protecting local interests in an ever more interconnected world.